NCT04216186 Role of Coenzyme Q in ADHD in Children
| NCT ID | NCT04216186 |
| Status | Recruiting |
| Phase | Phase 3 |
| Sponsor | Sherief Abd-Elsalam |
| Condition | ADHD |
| Study Type | INTERVENTIONAL |
| Enrollment | 40 participants |
| Start Date | 2018-11-01 |
| Primary Completion | 2030-12-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 3 trials are large pivotal studies comparing the treatment to current standard of care or placebo. Your participation directly contributes to the evidence needed for regulatory approval.
This trial targets 40 participants in total. It began in 2018-11-01 with a primary completion date of 2030-12-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Role of Coenzyme Q in ADHD in Children
Eligibility Criteria
Inclusion Criteria: * Patients with ADHD Exclusion Criteria: * Comorbidities like Autism, Anxiety, Obsessive compulsive disorder.
Contact & Investigator
Fatma G. Abdelkader, Msc
PRINCIPAL INVESTIGATOR
Pediatrics department - Kafr Elsheikh University
Frequently Asked Questions
Who can join the NCT04216186 clinical trial?
This trial is open to participants of all sexes, aged 2 Years or older, up to 18 Years, studying ADHD. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT04216186 trial and what does that mean for participants?
Phase 3 trials are large-scale studies comparing the new treatment to existing standards of care or a placebo. They provide the evidence needed for regulatory approval. This trial targets 40 participants.
Is NCT04216186 currently recruiting?
Yes, NCT04216186 is actively recruiting participants. Contact the research team at sheriefabdelsalam@yahoo.com for enrollment information.
Where is the NCT04216186 trial being conducted?
This trial is being conducted at Tanta, Egypt.
Who is sponsoring the NCT04216186 clinical trial?
NCT04216186 is sponsored by Sherief Abd-Elsalam. The principal investigator is Fatma G. Abdelkader, Msc at Pediatrics department - Kafr Elsheikh University. The trial plans to enroll 40 participants.